Zalicus Inc. and Epirus Biopharmaceuticals, Inc. agreed that Zalicus stockholders will own 19% of the combined company post-merger. In addition, Dr. Mark H.N. Corrigan will serve as chairman of the company's board of directors, which will have representatives from both the existing Epirus and Zalicus boards.